During the recent session, Cardiff Oncology Inc (NASDAQ:CRDF)’s traded shares were 0.53 million, with the beta value of the company hitting 1.76. At the last check today, the stock’s price was $4.48, reflecting an intraday gain of 3.23% or $0.14. The 52-week high for the CRDF share is $6.42, that puts it down -43.3 from that peak though still a striking 67.86% gain since the share price plummeted to a 52-week low of $1.44. The company’s market capitalization is $298.00M, and the average intraday trading volume over the past 10 days was 1.96 million shares, and the average trade volume was 1.95 million shares over the past three months.
Cardiff Oncology Inc (CRDF) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. CRDF has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.25.
Cardiff Oncology Inc (NASDAQ:CRDF) trade information
Cardiff Oncology Inc (CRDF) registered a 3.23% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 3.23% in intraday trading to $4.48, hitting a weekly high. The stock’s 5-day price performance is 14.29%, and it has moved by 68.42% in 30 days. Based on these gigs, the overall price performance for the year is 192.81%. The short interest in Cardiff Oncology Inc (NASDAQ:CRDF) is 9.95 million shares and it means that shorts have 2.92 day(s) to cover.
Cardiff Oncology Inc (CRDF) estimates and forecasts
Statistics show that Cardiff Oncology Inc has underperformed its competitors in share price, compared to the industry in which it operates. Cardiff Oncology Inc (CRDF) shares have gone up 99.11% during the last six months, with a year-to-date growth rate less than the industry average at -6.45% against 16.70. In the rating firms’ projections, revenue will increase 21.48% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 73k as predicted by 5 analyst(s). Meanwhile, a consensus of 5 analyst(s) estimates revenue growth to 76k by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 156k and 205k respectively. In this case, analysts expect current quarter sales to shrink by -53.21% and then drop by -62.93% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 35.42%. While earnings are projected to return -6.21% in 2025.
CRDF Dividends
Cardiff Oncology Inc is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Cardiff Oncology Inc (NASDAQ:CRDF)’s Major holders
Cardiff Oncology Inc insiders own 5.62% of total outstanding shares while institutional holders control 27.66%, with the float percentage being 29.30%. BLACKROCK INC. is the largest shareholder of the company, while 110.0 institutions own stock in it. As of 2024-06-30, the company held over 2.63 million shares (or 5.883% of all shares), a total value of $5.84 million in shares.
The next largest institutional holding, with 2.14 million shares, is of VANGUARD GROUP INC’s that is approximately 4.7816% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $4.74 million.
